ASX:BXN Bioxyne (BXN) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free BXN Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume174,489 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield2.51%Price TargetN/A Stock AnalysisStock Analysis Get Bioxyne alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About BioxyneBioxyne Limited, a life sciences and consumer health products company, manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines in the United Kingdom, Japan, Europe, and Australia. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, vitamins, manuka honey, skin care products, and mushroom complexes. It develops various functional food products, such as ingredients; and lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products. The company also provides product research and development services, and telemedicine services. In addition, it operates BLS Clinics, a telehealth platform. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. BXN Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive BXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioxyne and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorConsumer Defensive Industry Packaged Foods Sub-IndustryN/A Current SymbolASX:BXN CUSIPN/A CIKN/A Webwww.bioxyne.com Phone61 2 9078 8180FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,410,000.00 Net Margins-173.35% Pretax MarginN/A Return on Equity-414.39% Return on Assets-22.29% Debt Debt-to-Equity Ratio3.72 Current Ratio2.26 Quick Ratio2.30 Sales & Book Value Annual Sales$7.73 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.75 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,900,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.58 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Samuel WatsonCEO, MD & Executive DirectorMr. Guy Adrian Robertson B.Com. (Age 71)B.Comm(Hons.), CA, MAICD, CFO & Company Secretary Comp: $98.5kMr. Jason HineCOO & Executive DirectorMs. Rachel QianFinancial Controller & Assistant Company SecretaryKey Competitors1PM IndustriesOTCMKTS:OPMZAAK AB (publ.)OTCMKTS:ARHUFAmincorOTCMKTS:AMNCApotheca BiosciencesOTCMKTS:PCFPARIAKE JAPANOTCMKTS:AKEJFView All CompetitorsInsidersSamuel WatsonBought 20,000,000 shares on 10/13/2023Total: $260,000.00 ($0.01/share)Anthony (Tony) HoBought 500,000 shares on 10/6/2023Total: $6,000.00 ($0.01/share) This page (ASX:BXN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxyne Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.